ArticleNeurology. Genetics2026
Genetically Guided Pharmacotherapy for Structural Neurovascular Lesions.
Article in Neurology. Genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Structural neurovascular lesions (SNVLs)-arteriovenous malformations, cavernous malformations, and vein of Galen aneurysmal malformations, among others-have historically been treated using neurosurgical, radiotherapeutic, and endovascular approaches. However, lesion size, location, and presence of high-risk angioarchitectural features preclude many patients from receiving these treatments. Advances in human genetics and cerebrovascular biology have redefined SNVLs as dynamic, genetically driven lesions where sporadic cases are caused by somatic variants. Intriguingly, many SNVL-causing variants are also oncogenic and active drug targets. These data provide the rationale for a genetically driven taxonomy to guide targeted therapeutic selection. In this commentary, we synthesize efforts toward pharmacologic treatments of SNVLs and highlight how variant-specific or pathway-modulating therapies may be investigated, incorporating key considerations in molecular diagnosis, cerebrovascular biology, and molecular and phenotypic outcome measures, in forthcoming clinical trials. Together, these advances support the investigation of pharmacologic treatment strategies in carefully selected patients with SNVLs.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.